MEDACTA GROUP S.A. SF-,10

Medacta reports first-half group revenue of €368 million, which is 1% below analysts' expectations on a constant-currency basis (consensus €373 million). Constant-currency revenue growth was 9.7% versus an expected 11.5%, driven by strong gains in Asia‑Pacific (13.1%) and EMEA (10.0%), while North America grew only 6.6% on a constant-currency basis. Weaker performance was recorded in knee, spine, and shoulder and sports medicine; Medacta attributes the US slowdown in part to a sales reorganization in the spine division. The company confirms its full-year guidance of 10–14% constant-currency revenue growth and says it would need to achieve around 14.3% constant-currency growth in the second half to reach the midpoint. » More on de.investing.com

At its general meeting, Medacta approved a dividend of CHF 1.10 per share for 2025, an increase of 59.42% year‑on‑year, totalling CHF 13.74 million. The share closed at CHF 140.80 on the day of the meeting; the ex‑dividend date is May 6, 2026. The dividend yield rises to 0.70% (previous year 0.65%); the real one‑year return (price plus dividend) is 2.98%. FactSet expects an increase to €1.24 per share for 2026. » More on finanzen.net

Medacta reports adjusted EBIT of EUR 52m in the second half, slightly above consensus estimates, and adjusted EBITDA of EUR 92m, 3% ahead of consensus. Group revenue rose 17% on a currency-adjusted basis, but gross margins missed analysts' expectations. For 2026 management sees currency-adjusted revenue growth of 10–14% and a widening of the currency-adjusted EBITDA margin by 50 basis points; the mid‑term revenue forecast for 2024–27 was raised to 12–15%. » More on de.investing.com